Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study
Background Coronary artery ectasia (CAE) is characterized by abnormal coronary dilation and slow flow, predisposing patients to thrombotic complications. Optimal long-term antithrombotic strategies for CAE remain undefined. This study aimed to evaluate the efficacy and safety of low-dose rivaroxaban combined with singl...